Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

100% User Fees For US FDA? Trump Budget Revives Important Issue For Industry – But Not This Year

Executive Summary

Trump Administration’s surprising call for increased user fees probably won’t have much impact on pending reauthorization process, but it does put on the table an important question for the biopharma industry to consider for the long term: should FDA be fully funded by user fees?

Advertisement

Related Content

The Latest Furor Over Trump’s Drug Pricing Plan
Perspectives On Health Reform, User Fees With Cowen's Chris Krueger
Inspection Delays Remain For Novel Approvals By US FDA; Will Quality Office Help?
20 Drugs That Got Their Start, In Part, With US Public Funding
User Fees: Should US FDA Incur Penalties For Missed Deadlines?
FDA's No Comment On Budget Plans Leaves Awkward Void
The Freeze Thaws: US FDA Allowed To Hire Staff For Cures, User Fee Activity
FDA User Fee Hearing Hijacked By US Health Care Reform Arguments
Trump's Budget Outline Threatens User Fee Agreements
FDA and User Fees: Time to Give 100%?

Topics

Advertisement
UsernamePublicRestriction

Register

PS120300

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel